Joint Drugs Controller under CBI net for allegedly taking bribe to waive off clinical trial of Biocon's Insulin Aspart injection Ruchika Sharma21 Jun 2022 11:49 AM ISTDenying allegations, a Biocon Biologics spokesperson said, "All our product approvals are legitimate and backed by science and clinical data. Our...
Glasgow University inaugrates Mazumdar Shaw Advance Research Centre Ruchika Sharma10 Jun 2022 11:00 AM ISTBengaluru: The University of Glasgow has announced the official opening of the Mazumdar-Shaw Advanced Research Centre by the Nobel Laureate,...
Biocon Biologics gets CDSCO panel nod to import, manufacture Insulin Aspart Injection Dr. Divya Colin25 May 2022 4:23 PM ISTNew Delhi: Approving the waiver of Phase III clinical trial in the country, the Subject Expert Committee (SEC) functional under Central Drug Standard...
Biocon Biologics, Viatris launch cancer medicine Abevmy in Canada Ruchika Sharma20 May 2022 3:02 PM ISTAbevmy is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor (VEGF) and neutralizes its...
CCI approves Serum Institute Life Sciences-Biocon Biologics deal Medical Dialogues Bureau19 May 2022 3:12 PM ISTNew Delhi: The Competition Commission of India (CCI) has approved a proposed deal involving Serum Institute Life Sciences, Covidshield Technologies...
Biocon Biologics bags Rs 689 crore contract for Insugen from Malaysian Govt Ruchika Sharma27 April 2022 2:53 PM ISTThe rh-Insulin formulations, Insugen-R, Insugen-N and lnsugen-30/70, are manufactured at Biocon Sdn. Bhd.'s Johor facility.
Biocon Biologics Inpremzia gets backing from EMA expert panel Ruchika Sharma2 April 2022 12:43 PM ISTInpremzia is a pre-mixed ready-to-use insulin for IV infusion for patients in hospital and other acute care settings.
Biocon, Viatris application for Insulin Aspart rejected by USFDA Ruchika Sharma11 Jan 2022 3:30 PM ISTNew Delhi: Biocon Biologics, a subsidiary of biotechnology major Biocon, on Friday said the US health regulator has not approved an application for...
Biocon Biologics partner Viatris wins US court decision on 5 Sanofi Lantus SoloSTAR device patents Ruchika Sharma31 Dec 2021 5:12 PM ISTBengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced that the U.S. Court of Appeals for the Federal Circuit (USCAFC) has ...
Biocon arm gets DCGI nod to initiate clinical study for Itolizumab Ruchika Sharma24 Dec 2021 1:13 PM ISTItolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway.
Biocon Biologics, Viatris to offer Insulin Glargine by Walgreens Prescription Savings Club Ruchika Sharma20 Nov 2021 2:14 PM ISTBengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., and Viatris Inc. have confirmed that Insulin Glargine (insulin glargine-yfgn)...
Biocon Biologics, Viatris launch interchangeable biosimilars Semglee, Insulin Glargine injections in US Ruchika Sharma17 Nov 2021 11:30 AM ISTBengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., and Viatris Inc. today announced the U.S. launch of interchangeable biosimilars SEMGLEE...
